In terms of novel approaches, the [64Cu]-PSMA compound (included in Table S1) seems feasible for prostate cancer detection [163], [64Cu]-dichloride is used for copper trafficking in metabolic diseases [170,171], and [64Cu]-labeled peptides based on uPAR biomarkers (already developed and administrated to humans) can be used for glioblastoma [163]. The gene discussed is FOLH1; the disease is prostate carcinoma.